UCB Offers to Buy Schwarz Pharma
ePT--the Electronic Newsletter of Pharmaceutical Technology
UCB SA has offered EUR 4.4 billion ($5.64 billion) in cash and stocks to acquire Schwarz Pharma AG.
Frankfurt, Germany (Sept. 25)––UCB SA (Brussels, Belgium, www.ucb-group.com) has offered EUR 4.4 billion ($5.64 billion) in cash and stocks to acquire Schwarz Pharma AG (Monheim, Germany, www.schwarzpharma.com). If approved, the combined company will be called UCB and will be based in Brussels.
The UCB offer of EUR 50 per share ($64.09) in cash and 0.8735 UCB shares was accepted by the Schwarz family, which owns 60% of the stock. Schroders Investment Management Ltd. and Capital Research and Management, which combined hold nearly 8% of Schwarz’s stock, also agreed to the deal.
The deal would create a company with annual revenues of more than EUR 3 billion ($4.23 billion) and annual research and development spending of more than EUR 700 million (almost $1 billion).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
